Oncology
Pirtobrutinib Enters First-Line CLL and SLL Treatment
The FDA has moved pirtobrutinib into previously untreated CLL and SLL, expanding first-line choice when therapy is indicated rather than reserving the drug for later lines.
Rayan Salih · October 28, 2026 · 6 min